ADAndrea Vanessa Llanos Diaz

Andrea Vanessa Llanos Diaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Vanessa Llanos Diaz has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Alexis Germán Murillo Carrasco

    Center for Translational Research in Oncology (LIM24), Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), São Paulo 01246-000, Brazil, São Paulo, Brazil

    2 shared publications
  • Ana Granda Alacote

    Affiliation Universidad de San Martín de Porres, Facultad de Medicina Humana, Lima, Peru

    1 shared publication
  • Antonio Mauricio Sánchez Cotrina

    Affiliation Universidad de Piura, Lima, Perú

    1 shared publication
  • Daysi Zulema Diaz-Obregón

    Affiliation Universidad de San Martín de Porres, Facultad de Medicina Humana, Lima, Peru

    1 shared publication
  • Daysi Zulema Diaz-Obregón

    Research Directorate, Institute for Health Technology Assessment and Research (IETSI), Social Health Insurance of Peru (EsSalud), Lima, Peru

    1 shared publication
  • Gabriela Goyoneche Linares

    Affiliation ONG INNOVACARE, Lima, Perú

    1 shared publication

Latest Publications

  • Open Access

    Precision Nutraceuticals and Biomarkers of Healthy Aging: A Scoping Review of Human Studies on Nutrigenomic-Based Interventions

    by Andrea Vanessa Llanos-Díaz, Moisés Apolaya-Segura, Orlando R. Sevillano, Obert Marín-Sanchez, Jacinto Joaquín Vértiz Osores, Alexis Germán Murillo Carrasco, Sophie Nicole Llanos-Diaz, Daysi Zulema Diaz-Obregón

    Background: Precision nutrition and nutrigenomics have emerged as promising strategies to personalize dietary interventions according to individual genetic, metabolic, and molecular characteristics. However, the potential of nutrigenomic-guided nutraceutical interventions to modulate biological aging pathways remains poorly characterized. Objective: This study aimed to map and synthesize the available evidence from human studies evaluating personalized nutraceutical interventions based on nutrigenomic approaches and their effects on biomarkers associated with biological aging. Methods: A scoping review was conducted following the Joanna Briggs Institute methodology and PRISMA-ScR guidelines. PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched for studies published between 2021 and 2026. Eligible studies included adults aged ≥18 years receiving personalized nutraceutical interventions informed by genetic, genomic, metabolomic, or other molecular data. Outcomes included biomarkers of cellular aging, inflammation, oxidative stress, immunometabolism, and related pathways. Results: Twenty-one studies were included. Interventions involved omega-3 fatty acids, polyphenols, Nigella sativa, vitamin D, methyl-donor micronutrients, fermented papaya preparation, and other nutraceutical preparations and functional food-based interventions. Four major themes emerged: multi-omic stratification approaches, biological aging biomarkers, redox-inflammatory modulation, and applications in metabolic disorders. Most studies demonstrated favorable effects on intermediate molecular biomarkers, including inflammatory cytokines, oxidative stress markers, lipid metabolism, endothelial function, and DNA methylation signatures. However, evidence directly demonstrating slowing of biological aging through validated biomarkers such as epigenetic clocks or telomere dynamics remains limited. Conclusions: Personalized nutraceutical interventions exhibit biological plausibility for modulating pathways associated with healthy aging. Nevertheless, robust longitudinal studies incorporating validated biomarkers of biological aging and clinically meaningful outcomes are needed before their widespread implementation in precision medicine.

  • Open Access

    Variability of the lymphocyte-to-monocyte ratio in patients with chronic kidney disease on hemodialysis

    by Daysi Zulema Diaz-Obregón, Gabriela Goyoneche Linares, Ana Granda Alacote, Alexis G. Murillo Carrasco, Michael Bryant Castro Núñez, Andrea Vanessa Llanos Diaz, Katherine Susan Rufasto Goche, Antonio Mauricio Sánchez Cotrina, Víctor Arrunátegui Correa, Joel de León Delgado

    Introduction: Chronic kidney disease (CKD) is a global public health issue characterized by a state of persistent inflammation that leads to immune system dysregulation. The lymphocyte-to-monocyte ratio (LMR) has emerged as an inflammatory biomarker of interest for monitoring the progression of this condition. Objective: To determine the clinical-epidemiological, biochemical, and hematological characteristics associated with differences in the LMR in patients with chronic kidney disease undergoing hemodialysis. Materials and Methods: A retrospective cohort study was conducted by reviewing the medical records of 120 CKD patients on hemodialysis treated at a private nephrology center in Lima, Peru. Patients were divided into two groups based on the median LMR value: high LMR (< 3.06) and low LMR (≥ 3.06). Logistic regression was used to analyze risk factors associated with LMR variation, complemented by longitudinal regression analysis (up to three years follow-up). Results: The median age of the patients was 58 years at the time of analysis. Chronic glomerulonephritis, arterial hypertension, and type 2 diabetes mellitus (T2DM) were the most frequently reported causes of end-stage CKD. A total of 54.2% of patients had been on hemodialysis for more than seven years. Risk factors associated with decreased LMR, and thus with increased inflammation, were: older age (OR = 1.03, p < 0.001), more than three years on hemodialysis (OR = 2.17, p = 0.002), more than seven years on hemodialysis (OR = 2.38, p < 0.001), and presence of T2DM (OR = 2.2, p = 0.006). In addition, a direct positive contribution was found with hematocrit levels (Beta = 0.25, p < 0.001) and the presence of an arteriovenous fistula (Beta = 0.17, p = 0.038). Conclusions: A reduced LMR is a useful inflammatory biomarker for monitoring CKD severity. Increased age, prolonged duration of hemodialysis (more than three years), presence of T2DM, and elevated ferritin levels are associated with lower LMR values. In contrast, higher hematocrit levels and the presence of an arteriovenous fistula are directly associated with higher LMR values.